Browse Biomarkers Based on Source

This page shows data for Plasma source.
Total Entries Retrieved: 137
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
25 Insulin Like Growth Factor-1 (IGF-1) Protein Humans Dowregulated (Preintervention: 232.7 ± 20.6 ng/mL Vs Postintervention: 16.92 ± 23.3 ng/mL) Predictive Prostate Cancer patients pre and post treatment with Lycopene p=0.0002 Plasma 11489752
26 Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Protein Humans Dowregulated (Preintervention: 5230 ± 244 ng/mL Vs Postintervention: 3924 ± 298 ng/mL) Predictive Prostate Cancer patients pre and post treatment with Lycopene p=0.0002 Plasma 11489752
254 C-reactive protein (CRP) Protein Humans Increased in Overall Survival Prognostic Overall Survival Vs No Survival p<0.0001 Plasma 18428198
255 C-reactive protein (CRP) Protein Humans Increased in Overall Survival Prognostic PSA Decline Vs No PSA decline p=0.0068 Plasma 18428198
350 Transforming growth factor-β1 (TGF-β1) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
351 soluble IL-6 receptor (sIL-6R) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
352 IL-6 Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
353 Vascular endothelial growth factor (VEGF) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p= 0.002; Multivariate: p=0.008 Plasma 18559597
354 Vascular cell adhesion molecule-1 (VCAM-1) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
355 Endoglin Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p<0.001Multivariate: p=0.002 Plasma 18559597
356 Urokinase-type plasminogen activator (uPA) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
357 uPA receptor (uPAR) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p<0.001; Multivariate: p=0.05 Plasma 18559597
358 TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA + PAI-1 + uPAR Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years NA Plasma 18559597
359 TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years NA Plasma 18559597
417 Transforming growth factor-b1 Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.003 Plasma 19229851
418 Interleukin-6 soluble receptor ((IL-6sR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.001 Plasma 19229851
419 Interleukin-6 (IL-6) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001 Plasma 19229851
420 Vascular cell adhesion molecular 1 (VCAM 1) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
421 Vascular endothelial growth factor (VEGF) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p=0.002 Plasma 19229851
422 Endoglin Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
423 Urokinase-type plasminogen activator (uPA) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.036 Plasma 19229851
424 Urokinase-type plasminogen activator receptor (uPAR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
425 Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years NA Plasma 19229851
592 placental growth factor (PIGF) Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
593 soluble c-kit Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
594 VEGF Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
595 sVEGFR1 Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p=0.001 Plasma 21323568
679 miR-141 miRNA Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p<0.001 Plasma 21723797
680 Circulating Tumor Cells Others Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p=0.002 Plasma 21723797
681 Lactate Dehydrogenase (LDH) Metabolites Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p= 0.014 Plasma 21723797
772 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA Diagnostic Controls Vs Patients p<0.05 Plasma 21993000
777 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Plasma 21993000
780 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (No Treatment) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) Plasma 21993000
783 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>7 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Plasma 21993000
837 mir-107; mir-130b; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625; miRNA Humans Upregulated in PCa: [mir-107; mir-130b; mir-141; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;] Downregulated in PCa: [miR-181a-2* (2.69 fold)] Diagnostic Normal Vs prostate cancer p<0.001 Plasma 22240788
838 mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625; miRNA Humans Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)] Diagnostic Normal Vs localised prostate cancer p<0.001 Plasma 22240788
839 mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b miRNA Humans Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)] Diagnostic metastatic prostate cancer Vs localised prostate cancer p<0.001 Plasma 22240788
843 let-7c + let-7e+miR30c+ miR-622+ miR1285 miRNA Humans Differentially expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p<0.001 Plasma 22298030
844 let-7c + let-7e+miR30c+ miR-622+ miR1285 miRNA Humans Differentially expressed Diagnostic Prostate Cancer Vs Healthy Men p<0.001 Plasma 22298030
845 let-7c miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
846 let-7e miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
847 miR-30c miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
848 miR-622 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
849 miR-1285 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p=0.0047 Plasma 22298030
850 let-7c miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training & Testing: p<0.0001 Plasma 22298030
851 let-7e miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p=0.0029; Testing = p<0.0001 Plasma 22298030
852 miR-25 miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001; Not significant in validation set Plasma 22298030
853 miR-30c miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
854 miR-346 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001; Not significant in validation set Plasma 22298030
855 miR-622 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
856 miR-940 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p= 0.0062 Plasma 22298030
857 miR-1285 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
858 basic fibroblast growth factor (bFGF) Protein Humans Upregulated in Treatment Group: [Treatment: 32 (25–71) Vs Control : 11 (8–14)] Predictive ADT Treatment Vs No Treatment p=0.0006 Plasma 22302227
859 Interleukin 1 (IL-1β) Protein Humans Upregulated in Treatment Group [Treatment:0.56 (0.45–0.90) Vs Control : 0.34 (0.25–0.52)] Predictive ADT Treatment Vs No Treatment p=0.026 Plasma 22302227
860 Interleukin 8 (IL-8) Protein Humans Upregulated in Treatment Group (Treatment: 5.7 (3.8–7.7) Vs Control : 2.2 (1.6–2.8) ) Predictive ADT Treatment Vs No Treatment p=0.0001 Plasma 22302227
861 stromal cell–derived factor 1α (SDF-1α) Protein Humans Upregulated in Treatment Group (Treatment: 2,294 (1,775–2,671) Vs Control : 1,736 (1,577–1,842) ) Predictive ADT Treatment Vs No Treatment p=0.023 Plasma 22302227
862 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Prostate Cancer (Healthy: 10.36±0.69 ; BPH: 9.39±0.75; PCA: 6.89±0.58) Diagnostic Healthy Controls Vs BPH VS Prostate Cancer p <0.05 Plasma 22315056
863 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Stage 2 PCa than Stage 1 PCa Prognostic Stage 1 Vs Stage 2 prostate cancer p<0.001 Plasma 22315056
864 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Patients with No survival (No Survival: 5.11±0.75 Vs Survival: 7.02±0.22) Prognostic disease specific survival Vs no survival p=0.0439 Plasma 22315056
865 Erythrocyte sphingosine kinase-1 (SphK1) Protein Humans Downregulated in PCa (Healthy: 4.7±0.42; PCa: 2.14±0.17) Diagnostic Prostate Cancer Vs Healthy Men p<0.0001 Plasma 22315056
866 Testosterone Protein Humans Downregulated in Gleason Score 8-9 Prognostic Gleason Sum 5 Vs Gleason Sum 8-9 p=0.0495 Plasma 22315056
867 Testosterone Protein Humans Upregulated in Metastases Prognostic Metastases Vs No Metastases p<0.0001 Plasma 22315056
920 Deoxycarnitine; Acetylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Laurylcarnitine; Palmitoylcarnitine; Stearoylcarnitine; Oleoylcarnitine; 3-hydroxybutyrate (BHBA); Acetoacetate; Dodecanedioate; Octadecanedioate; Metabolites Humans Differentially expressed [ Deoxycarnitine (0.89 fold); Acetylcarnitine (0.80 fold); Hexanoylcarnitine (0.80 fold_; Octanoylcarnitine (0.72 fold); Decanoylcarnitine (0.71 fold); Laurylcarnitine (0.65 fold); Palmitoylcarnitine (0.82 fold0; Stearoylcarnitine (0.77 fold); Oleoylcarnitine (0.88 fold); 3-hydroxybutyrate (BHBA) (0.36 fold); Acetoacetate (0.52 fold); Dodecanedioate (0.80 fold); Octadecanedioate (0.73 fold);] Predictive Effect of Androgen deprivation therapy (ADT) baseline to 3 months <0.05 Plasma 22589396
932 Modification Status of RNF219 cirDNA Humans Highly modified in PCa Patients (Control: 55% Diagnostic PCA VS no history of prostate disease p=3 *10^-41 Plasma 22619380
933 Modification Status of RNF220 cirDNA Humans Highly modified in PCa Patients (Control: 55% Diagnostic PCA Vs BPH p = 1 *10^-4 Plasma 22619380
967 Osteopontin Protein Humans Upregulated in PCa Diagnostic PCa Vs BPH VS Healthy Donors p<0.05 Plasma 22870138
1012 Survivn Protein Humans Upregulated in PCA compared to both Healthy controls and BPH Diagnostic (Normal and BPH )VS PCa p<0.001 Plasma 23091600
1018 sICAM-1 Protein Humans Upregulated in PCa (PCa: 245.2 , Normal: 240.3) Diagnostic PCa Vs Controls p=0.005 Plasma 23171880
1019 CRP Protein Humans Upregulated in PCa (PCa: 2.5 , Normal: 2.1) Diagnostic PCa Vs Controls [Odds Ratio: p=0.03]; [Regulation: p = 0.006] Plasma 23171880
1027 Carbonic Anhydrase I Protein Humans Upregulated in PCa Diagnostic PCA Vs Healthy Controls p = 0.022 Plasma 23213568
1028 PSA + Carbonic Anhydrase I Protein Humans Upregulated in PCa Diagnostic PCA Vs Healthy Controls p = 0.022 Plasma 23213568
1091 miR-141 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1092 miR-375 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1093 miR-151-3p miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1094 miR-126 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1095 miR-16 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1096 miR-205 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1097 PSA + miR141 + mir-151-3p + mir-16 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1098 miR-423-3p miRNA Humans Upregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.002 Plasma 23574937
1099 miR-205 miRNA Humans Downregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.004 Plasma 23574937
1100 miR-205 miRNA Humans Upregulated in Biochemical Recurrence Prognostic Biochemical recurrence p = 0.006 Plasma 23574937
1101 miR-423-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1102 miR-151-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1156 Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Diagnostic Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate p< 0.0137 Plasma 23826311
1157 Peptide ID: [7098; 8863; 9673; 10706; 24050] Protein Humans Downregulated in PCa [mean(control)/mean (case)]: [Peptide ID: [7098 (3.3 fold) ; 8863 (7.7 fold) ; 9673(73.1 fold) ; 10706 (124.8 fold) ; 24050( 11.1 fold)] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p< 0.0027 Plasma 23826311
1158 21PP + 5PP Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.0001 Plasma 23826311
1159 Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Prognostic Localised Vs Advanced Prostate Cancer p=0.0055 Plasma 23826311
1206 Neuropeptide‐Y (NPY) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs (Normal and BPH patients) p = 0.0396 Plasma 23991666
1207 Neuropeptide‐Y (NPY) + Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs (Normal and BPH patients) p = 0.0396 Plasma 23991666
1248 Thrombospondin-1 [TSP-1] Protein Humans Increased levels indicate better overall survival in Tasquinimod arm Predictive Overall Survival in Tasquinimod Vs Overall Survival in Placebo arm p=0.034 Plasma 24255071
1331 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine + Plasma 24512523
1332 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Urine + Plasma 24512523
1393 Testosterone Hormone Humans Increased levels in patients with Higher overall Survival Prognostic Overall Survival Vs No Survival p=0.018 Plasma 24722180
1394 Testosterone Hormone Humans Lower levels in Non Responders Predictive PSA Responders Vs Non Responder p=0.0196 Plasma 24722180
1496 miR-1290 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1497 miR-1246 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1498 miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1499 miR-1290 + miR-375 + PSA + ADT miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p= 0.0016 Plasma 25129854
1500 miR-1290 + miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.05 Plasma 25129854
1509 Base model (Age and total PSA) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Plasma 25151013
1510 Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Plasma 25151013
1511 Prostate Health Index (PHI) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Plasma 25151013
1512 Base model (Age and total PSA) Protein Humans NA Diagnostic High-grade Prostate cancer NA Plasma 25151013
1513 Four-kallikrein panel (Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]) Protein Humans NA Diagnostic High-grade Prostate cancer p<0.0001 Plasma 25151013
1514 Prostate Health Index (PHI) Protein Humans NA Diagnostic High-grade Prostate cancer p<0.0001 Plasma 25151013
1604 Full Length Androgen Receptor (AR-FL) mRNA Humans NA Prognostic Progression-free survival Vs No Progression-free survival p=0.0003 Plasma 31055861
1655 miR‐28; miR‐100; miR‐942; miR‐28‐3p miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐28: p=0.016; miR‐100: p=0.025; miR‐942: p=0.025; miR‐28‐3p: p=0.038 Plasma 30958910
1656 miR‐708; miR‐1298; miR‐886‐3p; miR‐374; miR‐376c; miR‐202; miR‐128a; miR‐185 miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐708: p<0.001; miR‐1298: p=0.001; miR‐886‐3p:p=0.01; miR‐374:p=0.017; miR‐376c: p=0.031; miR‐202: p=0.035; miR‐128a: p=0.039; miR‐185: p=0.041 Plasma 30958910
2025 LPC(18∶1) Metabolites Humans Methylated in systemic Recurrence Diagnostic Patients Vs Controls 2.63E-09 Plasma 23152813
2026 LPC(20∶4) Metabolites Humans Methylated in systemic Recurrence Diagnostic Patients Vs Controls 1.71E-15 Plasma 23152813
2027 PC(40∶7) Metabolites Humans Methylated in systemic Recurrence Diagnostic Patients Vs Controls 4.37E-11 Plasma 23152813
2028 LPC(18∶0) Metabolites Humans Upregulated with fold change of 2.7 Diagnostic Patients Vs Controls 3.00E-08 Plasma 23152813
2029 LPC(16∶0) Metabolites Humans Upregulated with fold change of 3.2 Diagnostic Patients Vs Controls 2.03E-06 Plasma 23152813
2030 ePC(38∶4) Metabolites Humans Upregulated with fold change of 2.2 Diagnostic Patients Vs Controls 3.01E-08 Plasma 23152813
2031 PC(38∶4) Metabolites Humans Upregulated with fold change of 2.5 Diagnostic Patients Vs Controls 3.65E-05 Plasma 23152813
2032 PC(38∶5) Metabolites Humans Upregulated with fold change of 2.8 Diagnostic Patients Vs Controls 8.50E-06 Plasma 23152813
2033 SM(18∶1) Metabolites Humans Upregulated with fold change of 2.1 Diagnostic Patients Vs Controls 1.05E-09 Plasma 23152813
2034 SM(16∶1) Metabolites Humans Upregulated with fold change of 2.1 Diagnostic Patients Vs Controls 6.71E-09 Plasma 23152813
2035 DSM(16∶0) Metabolites Humans Upregulated with fold change of 2.2 Diagnostic Patients Vs Controls 3.85E-19 Plasma 23152813
2036 SM(16∶0) Metabolites Humans Upregulated with fold change of 3 Diagnostic Patients Vs Controls 1.20E-06 Plasma 23152813
2037 ePC(36∶1) Metabolites Humans Upregulated with fold change of 2.5 Diagnostic Patients Vs Controls 6.30E-10 Plasma 23152813
2038 SM(18∶0) Metabolites Humans Upregulated with fold change of 22.7 Diagnostic Patients Vs Controls 1.72E-06 Plasma 23152813
2039 ePC(36∶2) Metabolites Humans Upregulated with fold change of 2.5 Diagnostic Patients Vs Controls 1.72E-07 Plasma 23152813
2040 LPC(18:1)+LPC(20:4) Metabolites Humans Upregulated with fold change of 2.4 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2041 LPC(18:1)+LPC(20:4)+PC(40:7) Metabolites Humans Upregulated with fold change of 2.8 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2042 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0) Metabolites Humans Upregulated with fold change of 2 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2043 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0) Metabolites Humans Upregulated with fold change of more than 2 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2044 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4) Metabolites Humans Upregulated with fold change of more than 3 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2045 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4) Metabolites Humans Upregulated with fold change of more than 4 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2046 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5) Metabolites Humans Upregulated with fold change of more than 5 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2047 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1) Metabolites Humans Upregulated with fold change of more than 6 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2048 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1) Metabolites Humans Upregulated with fold change of more than 7 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2049 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0) Metabolites Humans Upregulated with fold change of more than 8 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2050 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0) Metabolites Humans Upregulated with fold change of more than 9 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2051 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1) Metabolites Humans Upregulated with fold change of more than 10 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2052 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0) Metabolites Humans Upregulated with fold change of more than 11 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2053 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0)+ePC(36:2) Metabolites Humans Upregulated with fold change of more than 12 Diagnostic Patients Vs Controls <0.001 Plasma 23152813